Nexalin Technology Announces Reverse Stock Split
Rhea-AI Summary
Nexalin Technology (Nasdaq: NXL) has approved a 1-for-30 reverse stock split of its common stock to help ensure continued compliance with the Nasdaq bid-price rule. Stockholders previously approved future reverse splits and authorized the board to set exact ratios and timing.
The reverse split becomes effective on August 28, 2026 at 5:00 p.m. ET, with trading on a split-adjusted basis on the Nasdaq Capital Market expected to begin on August 31, 2026 under the unchanged ticker NXL and new CUSIP 65345B300. Every 30 issued and outstanding shares will be combined into one share, while par value remains $0.001. No fractional shares will be issued; eligible holders will receive proportional cash payments. Continental Stock Transfer & Trust will act as exchange agent, and shareholders holding in book-entry or street name are not required to take action.
Positive
- 1-for-30 reverse split approved to support Nasdaq bid-price rule compliance
- Trading continuity maintained with unchanged Nasdaq ticker NXL and automatic position adjustments
Negative
- Common share count consolidated at a high 1-for-30 reverse split ratio
- Need for reverse split highlights reliance on Nasdaq bid-price rule compliance
News Explained
For existing holders, the 1-for-30 split reduces the share count and proportionally raises the per-share price, while the split itself does not change the company’s value.
Market reaction after 1-for-30 reverse split: NXL -20.41%
Following this news, NXL has declined 20.41%, reflecting a significant negative market reaction. Our momentum scanner has triggered 5 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $0.23.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 23 | clinical trial award | Positive | -3.2% | Clinical investigator received Young Researcher Award for Brazilian trial research |
| Jun 16 | clinical abstracts | Positive | -2.8% | Two abstracts presented preliminary neuromodulation results across multiple conditions |
| Jun 10 | clinical trial results | Positive | +2.0% | Brazilian trial reported anxiety response and durable benefits |
| Jun 04 | patent issuance | Positive | +1.4% | U.S. patent issued covering dynamic frequency stimulation method |
| May 21 | legislative provision | Positive | +19.1% | House report language supported additional VA neurostimulation research |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
NXL's recent positive clinical and corporate announcements produced mixed outcomes, with three gains and two declines.
Key Terms
reverse stock split financial
bid-price rule regulatory
cusip number technical
book-entry form technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
HOUSTON, TX, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), announces that its board of directors has approved a 1-for-30 reverse stock split of the Company’s common stock, to ensure continued compliance with the Nasdaq bid-price rule. The Company’s stockholders approved future reverse stock splits, their timing, and granted the board of directors authority to determine future exact split ratios.
The reverse stock split will become effective on August 28, 2026, at 5:00 pm, Eastern Time (the “Effective Time”), and the Company’s common stock is expected to begin trading on a reverse stock split-adjusted basis on The Nasdaq Capital Market (“Nasdaq”) at market open under the existing ticker symbol, “NXL” on August 31, 2026, the date which has been approved by Nasdaq for the effectiveness of such split.
As of the Effective Time, every 30 shares of the Company’s issued and outstanding common stock will be combined into one share of common stock. The par value per share of the Company’s common stock will remain unchanged at
The Company’s common stock will continue to trade on Nasdaq under the symbol “NXL” following the reverse stock split, with a new CUSIP number of 65345B300. No fractional shares will be issued in connection with the reverse stock split, and stockholders who would otherwise be entitled to a fractional share will receive a proportional cash payment.
The Company’s transfer agent, Continental Stock Transfer & Trust Co., will serve as the exchange agent for the reverse stock split. Registered stockholders holding pre-reverse stock split shares of common stock electronically in book-entry form are not required to take any action to receive post-reverse stock split shares. Those stockholders who hold their shares in brokerage accounts or in “street name” will have their positions automatically adjusted to reflect the reverse stock split, subject to each broker’s particular processes, and will not be required to take any action in connection with the reverse stock split.
About Nexalin Technology, Inc.
Nexalin designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. Nexalin’s medical devices are non-invasive and undetectable to the human body. Nexalin believes its neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with mental health disorders, and that the deeper-penetrating waveform in its next-generation devices, including the HALO™ Clarity, will generate enhanced patient response without adverse side effects. The Nexalin Gen-2 SYNC 15 milliamp neurostimulation device has been approved in China, Brazil, Oman, and Israel. Additional information is available at www.nexalin.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release, including statements regarding Nexalin’s future results of operations and financial position, Nexalin’s business strategy, prospective product candidates, product approvals, research and development costs, timing and likelihood of success, plans and objectives of management for future operations, future results of current and anticipated studies and business endeavors with third parties, and future results of current and anticipated product candidates, are forward-looking statements. These forward-looking statements relate to future events, future performance, or management’s current expectations, beliefs, assumptions, plans, estimates, intentions, or projections relating to the future, and are not guarantees of future performance. Any statements that are not statements of historical fact, or that refer to expectations, projections, or other characterizations of future events or circumstances (including, without limitation, statements containing the words “believes,” “expects,” “anticipates,” “plans,” “intends,” “will,” “may,” “could,” “should,” “would,” “designed to,” “positioned to,” “potential,” “targeted,” “seeking,” “continues,” “strategy,” “opportunity,” “estimates,” “projects,” “forecasts,” “predicts,” “outlook,” “guidance,” or similar expressions, or the negative of such terms), are forward-looking statements. These statements are based on Nexalin’s current expectations, assumptions, and beliefs and are subject to a number of risks and uncertainties that could cause actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statements. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this press release.
Contact:
Crescendo Communications, LLC
Tel: (212) 671-1020
Email: NXL@crescendo-ir.com
